Clinical Trial Update: Pharmacokinetics, Pharmacodynamics And Safety Study Of Elelyso(tm) In Pediatric Subjects With Type 1 Gaucher Disease [Phase 4]

View source ↗

Summary

Phase 4 pharmacokinetics/pharmacodynamics and safety study of Elelyso in pediatric patients with Type 1 Gaucher Disease was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Gaucher Disease

Drugs mentioned

• ELELYSO (TALIGLUCERASE ALFA)

Snippet

Sponsor: Pfizer | Conditions: Type 1 Gaucher Disease | Phase 4 | Status: WITHDRAWN